Vestmark Advisory Solutions Inc. Increases Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Vestmark Advisory Solutions Inc. lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 7.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,120 shares of the medical research company’s stock after acquiring an additional 1,231 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Charles River Laboratories International were worth $4,284,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Commonwealth Equity Services LLC raised its holdings in Charles River Laboratories International by 9.4% in the third quarter. Commonwealth Equity Services LLC now owns 30,720 shares of the medical research company’s stock valued at $6,021,000 after buying an additional 2,643 shares during the period. Xponance Inc. raised its holdings in Charles River Laboratories International by 4.7% in the third quarter. Xponance Inc. now owns 7,389 shares of the medical research company’s stock valued at $1,448,000 after buying an additional 335 shares during the period. Raymond James & Associates raised its holdings in Charles River Laboratories International by 2.4% in the third quarter. Raymond James & Associates now owns 252,176 shares of the medical research company’s stock valued at $49,421,000 after buying an additional 6,013 shares during the period. Stratos Wealth Partners LTD. raised its holdings in Charles River Laboratories International by 24.5% in the third quarter. Stratos Wealth Partners LTD. now owns 2,505 shares of the medical research company’s stock valued at $491,000 after buying an additional 493 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in Charles River Laboratories International by 1.9% in the third quarter. Bank of New York Mellon Corp now owns 412,453 shares of the medical research company’s stock valued at $80,833,000 after buying an additional 7,590 shares during the period. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Charles River Laboratories International news, VP William D. Barbo sold 4,050 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total value of $1,006,425.00. Following the sale, the vice president now directly owns 22,879 shares in the company, valued at $5,685,431.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Charles River Laboratories International news, EVP Victoria L. Creamer sold 5,000 shares of the firm’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the sale, the executive vice president now directly owns 13,550 shares in the company, valued at $3,437,635. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP William D. Barbo sold 4,050 shares of the firm’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the completion of the sale, the vice president now owns 22,879 shares in the company, valued at $5,685,431.50. The disclosure for this sale can be found here. Insiders sold a total of 14,932 shares of company stock valued at $3,693,663 over the last 90 days. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock traded up $3.58 during mid-day trading on Friday, reaching $233.47. The company’s stock had a trading volume of 466,193 shares, compared to its average volume of 482,082. The firm has a market cap of $12.03 billion, a price-to-earnings ratio of 25.35, a PEG ratio of 1.80 and a beta of 1.44. The business has a 50 day moving average price of $252.23 and a 200-day moving average price of $223.97. The company has a current ratio of 1.52, a quick ratio of 1.16 and a debt-to-equity ratio of 0.73. Charles River Laboratories International, Inc. has a twelve month low of $161.65 and a twelve month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.39 by $0.07. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The firm’s revenue was down 7.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.98 earnings per share. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 11.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. TheStreet upgraded shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. Citigroup increased their price objective on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a research report on Thursday, February 15th. Argus increased their price objective on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, March 18th. Robert W. Baird increased their price objective on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the company an “outperform” rating in a research report on Thursday, February 15th. Finally, Evercore ISI increased their price objective on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the company an “outperform” rating in a research report on Thursday, February 15th. Five investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $253.23.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).